MicroPort Scientific (853) H1 2024 earnings summary

Executive summary

• Revenue rose 17.0% year-over-year (excluding FX impact) to US$558.7 million for 1H2024, driven by strong growth across all major business segments and robust international expansion.

• Gross profit increased 14.6% to US$330.6 million, while net loss narrowed by 51.5% to US$106.7 million; non-HKFRS adjusted net loss decreased 63.1% to US$68.4 million.

• Operating expense ratio improved from 94% to 64%, with R&D expense ratio dropping from 39% to 21% due to cost optimization and focus on core businesses.

• Overseas revenue surged 44% year-over-year, now accounting for 45.2% of total revenue.

• Strategic transformation included divestment of non-core assets, cost control, and innovation focus.

Financial highlights

• Gross profit margin remained stable at 59.2% (vs. 59.8% in 1H2023).

• R&D expenses decreased by 38.6% year-over-year to US$115.0 million; administrative and sales & marketing expenses also declined.

• Finance costs rose 30% to US$48.4 million due to higher borrowings and convertible bond interest.

• Cash and cash equivalents decreased to US$740.1 million (from US$1,019.6 million at year-end 2023).

• Net current assets rose to US$995.3 million from US$646.5 million at year-end 2023.

Outlook and guidance

• Focus remains on global expansion, innovation, operational efficiency, and core business consolidation.

• Ongoing investment in R&D for new product launches and regulatory approvals in key markets.

• Continued cost control, resource focus, and divestiture of non-core businesses planned.